Literature DB >> 3021807

Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay.

L J Anderson, C Tsou, R A Parker, T L Chorba, H Wulff, P Tattersall, P P Mortimer.   

Abstract

Acute-phase serum from a patient with aplastic crisis provided sufficient human parvovirus B19 to make a monoclonal antibody against B19 and to develop antigen and immunoglobulin M (IgM) and IgG antibody detection enzyme-linked immunosorbent assays (ELISAs). The indirect capture antibody method was used for all three assays. Antigen was detected in 8 of 29 sera drawn within 2 days of onset of illness from patients with aplastic crisis. These sera had high titers of virus by electron microscopy and DNA hybridization and had no detectable B19 antibody. Antigen was not detected in serum specimens that had low titers of B19 DNA and had B19 antibody. With the IgM ELISA, we detected B19 IgM in over 85% of clinical cases of aplastic crisis and fifth disease and less than 2% of controls. The prevalence of B19 IgG antibodies increased with age. Approximately 2% of children less than 5 years of age and 49% of adults greater than 20 years of age had B19 IgG antibodies. The B19 antibody ELISAs are sensitive and specific tests to detect B19 infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021807      PMCID: PMC268963          DOI: 10.1128/jcm.24.4.522-526.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency.

Authors:  J R Duncan; C B Potter; M D Cappellini; J B Kurtz; M J Anderson; D J Weatherall
Journal:  Lancet       Date:  1983-07-02       Impact factor: 79.321

2.  Parvovirus infections and hypoplastic crisis in sickle-cell anaemia.

Authors:  J R Pattison; S E Jones; J Hodgson; L R Davis; J M White; C E Stroud; L Murtaza
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

3.  The emerging story of a human parvovirus-like agent.

Authors:  M J Anderson
Journal:  J Hyg (Lond)       Date:  1982-08

4.  Occurrence of infection with a parvovirus-like agent in children with sickle cell anaemia during a two-year period.

Authors:  M J Anderson; L R Davis; J Hodgson; S E Jones; L Murtaza; J R Pattison; C E Stroud; J M White
Journal:  J Clin Pathol       Date:  1982-07       Impact factor: 3.411

5.  Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia.

Authors:  U M Saarinen; T L Chorba; P Tattersall; N S Young; L J Anderson; E Palmer; P F Coccia
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

6.  Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent.

Authors:  G R Serjeant; J M Topley; K Mason; B E Serjeant; J R Pattison; S E Jones; R Mohamed
Journal:  Lancet       Date:  1981-09-19       Impact factor: 79.321

7.  Infection with parvovirus-like virus and aplastic crisis in chronic hemolytic anemia.

Authors:  K R Rao; A R Patel; M J Anderson; J Hodgson; S E Jones; J R Pattison
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

8.  Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV).

Authors:  B J Cohen; P P Mortimer; M S Pereira
Journal:  J Hyg (Lond)       Date:  1983-08

9.  Parvovirus-like particles in human sera.

Authors:  Y E Cossart; A M Field; B Cant; D Widdows
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

10.  Hypothesis: the aplastic crisis of hereditary spherocytosis is due to a single transmissible agent.

Authors:  P P Mortimer
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

View more
  41 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

Review 2.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

3.  New oligopeptide immunoglobulin G test for human parvovirus B19 antibodies.

Authors:  T F Schwarz; S Modrow; B Hottenträger; B Höflacher; G Jäger; W Scharti; R Sumazakl; H Wolf; J Middeldorp; M Roggendorf
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 4.  Simian parvoviruses: biology and implications for research.

Authors:  Meredith A Simon
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

Review 5.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

6.  Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy.

Authors:  Sung-Hsin Kuo; Liang-In Lin; Chee-Jen Chang; Yun-Ru Liu; Kuo-Sin Lin; Ann-Lii Cheng
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

Authors:  M Bielaszewska; I Clarke; M A Karmali; M Petric
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

8.  The human parvovirus B19 non-structural protein 1 N-terminal domain specifically binds to the origin of replication in the viral DNA.

Authors:  Sunil Kumar Tewary; Haiyan Zhao; Xuefeng Deng; Jianming Qiu; Liang Tang
Journal:  Virology       Date:  2013-12-20       Impact factor: 3.616

Review 9.  Parvovirus B19 infection.

Authors:  J R Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

10.  Low prevalence of antibody to human parvovirus B19 in Singapore.

Authors:  Y Matsunaga; K T Goh; E Utagawa; N Muroi
Journal:  Epidemiol Infect       Date:  1994-12       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.